Shoshana M Rosenberg1, Keith J Petrie2, Annette L Stanton3,4, Lan Ngo1, Emma Finnerty1, Ann H Partridge1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2. Department of Psychological Medicine, University of Auckland, Auckland, New Zealand. 3. Jonsson Comprehensive Cancer Center, Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA. 4. Department of Psychiatry/Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA.
Abstract
BACKGROUND: As new targeted oral antineoplastic therapies have emerged in recent years, the development of effective strategies that promote optimal adherence to cancer medication regimens has become an important priority. METHODS: We conducted a scoping literature review to search for English language articles published through July 15, 2019, to identify studies that reported the testing and/or evaluation of interventions to improve adherence to oral antineoplastic agents. RESULTS: A total of 56 articles were selected for review. Of the studies evaluated, 14 were randomized trials. All interventions except two targeted adult patients. Thirty-three studies enrolled fewer than 100 patients. Most interventions were education- and counseling-based and centered on provision of information about the drug and strategies to manage side effects. Only eight studies used an mHealth tool and/or text messages to target nonadherence. Among studies with a comparison sample, fewer than one-half (44.7%) reported statistically significant improvements in adherence or persistence associated with the intervention; however, some pharmacist-directed programs, particularly those that integrated monitoring or routine follow-up with a provider, did demonstrate efficacy. CONCLUSION: Although the development of adherence-promoting interventions for oral antineoplastic therapies has increased recently, few have been rigorously tested. The nascent literature suggests those that are pharmacist directed and use regular monitoring show promise, though additional prospective studies are needed. Study methodology, population selection, and potential challenges that may be encountered in the implementation and dissemination phases should be considered when developing new interventions to address nonadherence to oral antineoplastic treatment.
BACKGROUND: As new targeted oral antineoplastic therapies have emerged in recent years, the development of effective strategies that promote optimal adherence to cancer medication regimens has become an important priority. METHODS: We conducted a scoping literature review to search for English language articles published through July 15, 2019, to identify studies that reported the testing and/or evaluation of interventions to improve adherence to oral antineoplastic agents. RESULTS: A total of 56 articles were selected for review. Of the studies evaluated, 14 were randomized trials. All interventions except two targeted adult patients. Thirty-three studies enrolled fewer than 100 patients. Most interventions were education- and counseling-based and centered on provision of information about the drug and strategies to manage side effects. Only eight studies used an mHealth tool and/or text messages to target nonadherence. Among studies with a comparison sample, fewer than one-half (44.7%) reported statistically significant improvements in adherence or persistence associated with the intervention; however, some pharmacist-directed programs, particularly those that integrated monitoring or routine follow-up with a provider, did demonstrate efficacy. CONCLUSION: Although the development of adherence-promoting interventions for oral antineoplastic therapies has increased recently, few have been rigorously tested. The nascent literature suggests those that are pharmacist directed and use regular monitoring show promise, though additional prospective studies are needed. Study methodology, population selection, and potential challenges that may be encountered in the implementation and dissemination phases should be considered when developing new interventions to address nonadherence to oral antineoplastic treatment.
Authors: Sandra L Spoelstra; Alla Sikorskii; Atreyee Majumder; Peggy S Burhenn; Monica Schueller; Barbara Given Journal: Clin J Oncol Nurs Date: 2017-04-01 Impact factor: 1.027
Authors: Sandra L Spoelstra; Charles W Given; Alla Sikorskii; Constantinos K Coursaris; Atreyee Majumder; Tracy DeKoekkoek; Monica Schueller; Barbara A Given Journal: Telemed J E Health Date: 2015-12-30 Impact factor: 3.536
Authors: Patrick Neven; Christos Markopoulos; Minna Tanner; Michel Marty; Rolf Kreienberg; Louise Atkins; Ann Franquet; Michael Gnant; Silvia Neciosup; Petra Tesarova; Sandro Barni; Veronique Deschamp Journal: Breast Date: 2014-03-24 Impact factor: 4.380
Authors: Lucien Noens; Marie-Anne van Lierde; Robrecht De Bock; Gregor Verhoef; Pierre Zachée; Zwi Berneman; Philippe Martiat; Philippe Mineur; Koen Van Eygen; Karen MacDonald; Sabina De Geest; Tara Albrecht; Ivo Abraham Journal: Blood Date: 2009-04-06 Impact factor: 22.113
Authors: Alfred I Neugut; Xiaobo Zhong; Jason D Wright; Melissa Accordino; Jingyan Yang; Dawn L Hershman Journal: JAMA Oncol Date: 2016-10-01 Impact factor: 31.777
Authors: Amanda Pereira-Salgado; Jennifer A Westwood; Lahiru Russell; Anna Ugalde; Bronwen Ortlepp; John F Seymour; Phyllis Butow; Lawrence Cavedon; Kevin Ong; Sanchia Aranda; Sibilah Breen; Suzanne Kirsa; Andrew Dunlevie; Penelope Schofield Journal: JMIR Mhealth Uhealth Date: 2017-12-06 Impact factor: 4.773
Authors: Claire C Conley; McKenzie McIntyre; Nicole A Pensak; Filipa Lynce; Deena Graham; Roohi Ismail-Khan; Katherine Lopez; Susan T Vadaparampil; Suzanne C O'Neill Journal: Breast Cancer Res Treat Date: 2022-01-07 Impact factor: 4.872
Authors: Kapeena Sivakumaran; Pamela K Ginex; Haya Waseem; Sarah M Belcher; Sarah Lagler-Clark; Kristine B LeFebvre; Nicole Palmer; Tejanth Pasumarthi; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803
Authors: Courtney P Williams; Amy Davidoff; Michael T Halpern; Michelle Mollica; Kathleen Castro; Benjamin Allaire; Janet S de Moor Journal: JCO Oncol Pract Date: 2022-08
Authors: Nancy L Keating; Gabriel A Brooks; Mary Beth Landrum; Pang-Hsiang Liu; Robert Wolf; Lauren E Riedel; Nirav S Kapadia; Shalini Jhatakia; Amanda Tripp; Carol Simon; Van Doren Hsu; Colleen M Kummet; Andrea Hassol Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816
Authors: Deborah R Kaye; Lauren E Wilson; Melissa A Greiner; Lisa P Spees; Jessica E Pritchard; Tian Zhang; Craig E Pollack; Daniel George; Charles D Scales; Chris D Baggett; Cary P Gross; Michael S Leapman; Stephanie B Wheeler; Michaela A Dinan Journal: J Geriatr Oncol Date: 2022-02-04 Impact factor: 3.929
Authors: Thu Ha Dang; Abdur Rahim Mohammad Forkan; Nilmini Wickramasinghe; Prem Prakash Jayaraman; Marliese Alexander; Kate Burbury; Penelope Schofield Journal: JMIR Cancer Date: 2022-04-27
Authors: Irene D Lin; Matthew B Shotts; Ahmad Al-Hader; Kellie Jones Weddle; Richard J Holden; Emily L Mueller; Monica R Macik; Mirian Ramirez; Ephrem Abebe Journal: PLoS One Date: 2022-09-22 Impact factor: 3.752
Authors: Catherine Goetzinger; Caroline Alleaume; Anna Schritz; Bernard Vrijens; Marie Préau; Guy Fagherazzi; Laetitia Huiart Journal: Front Pharmacol Date: 2022-09-27 Impact factor: 5.988